SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Badreddin Edris Sells 20,000 Shares

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Badreddin Edris sold 20,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $54.23, for a total value of $1,084,600.00. Following the completion of the sale, the chief operating officer now directly owns 169,712 shares in the company, valued at approximately $9,203,481.76. The trade was a 10.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Badreddin Edris also recently made the following trade(s):

• On Monday, February 10th, Badreddin Edris sold 30,000 shares of SpringWorks Therapeutics stock. The stock was sold at an average price of $53.13, for a total value of $1,593,900.00.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX opened at $50.59 on Thursday. SpringWorks Therapeutics, Inc. has a one year low of $28.21 and a one year high of $62.00. The stock has a market capitalization of $3.79 billion, a P/E ratio of -14.54 and a beta of 0.76. The firm’s 50 day simple moving average is $43.86 and its two-hundred day simple moving average is $38.66.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The business had revenue of $61.55 million during the quarter, compared to analysts’ expectations of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. As a group, equities analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Huntington National Bank grew its position in SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after acquiring an additional 192 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after purchasing an additional 414 shares during the period. State of Wyoming boosted its stake in shares of SpringWorks Therapeutics by 39.5% during the fourth quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after purchasing an additional 433 shares during the period. Barclays PLC grew its holdings in shares of SpringWorks Therapeutics by 0.3% in the fourth quarter. Barclays PLC now owns 156,123 shares of the company’s stock worth $5,641,000 after purchasing an additional 447 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of SpringWorks Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after buying an additional 474 shares during the period.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research report on Friday, February 21st. Guggenheim lowered their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Evercore ISI upped their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, Wedbush reissued an “outperform” rating and issued a $81.00 target price on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics has an average rating of “Buy” and an average price target of $73.20.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.